Difficulty: Medium
Average Score: 64%
Practice
A nurse is reviewing a medical record of a patient who's been prescribed inhalable anticholinergics for recurring allergen-induced bronchospasms. Which of the following conditions will be a common contraindication for this drug?
Correct answer
A
Rationale
In the context of advanced pharmacology across the lifespan, understanding contraindications for specific medications is crucial for safe and effective patient care. In this scenario, the correct answer is option A) Peanut allergy. Inhalable anticholinergics, such as ipratropium bromide, can contain soya lecithin as an excipient, which is derived from soybean oil. Individuals with peanut allergies may also have cross-reactivity to soy products due to similarities in protein structures, potentially leading to an allergic reaction. This contraindication is important to prevent adverse reactions and ensure patient safety.
Option B) Penicillin allergy, option C) Shellfish allergy, and option D) Iodine allergy are incorrect choices in this scenario. Penicillin, shellfish, and iodine allergies do not typically contraindicate the use of inhalable anticholinergics for allergen-induced bronchospasms. These allergies are unrelated to the components typically found in these medications and would not pose a direct risk to patients using inhalable anticholinergics.
Educationally, this question highlights the importance of considering not only the primary medication but also its excipients when assessing for contraindications in patients with known allergies. It underscores the need for healthcare providers to have a comprehensive understanding of medication components and their potential interactions with patients' existing medical conditions to provide safe and individualized care.
Option B) Penicillin allergy, option C) Shellfish allergy, and option D) Iodine allergy are incorrect choices in this scenario. Penicillin, shellfish, and iodine allergies do not typically contraindicate the use of inhalable anticholinergics for allergen-induced bronchospasms. These allergies are unrelated to the components typically found in these medications and would not pose a direct risk to patients using inhalable anticholinergics.
Educationally, this question highlights the importance of considering not only the primary medication but also its excipients when assessing for contraindications in patients with known allergies. It underscores the need for healthcare providers to have a comprehensive understanding of medication components and their potential interactions with patients' existing medical conditions to provide safe and individualized care.